Apalutamide for the treatment of non-metastatic prostate cancer

Apalutamide (Erleada) is a selective androgen-receptor inhibitor licensed for the treatment of non-metastatic castration-resistant prostate cancer in men who are at high risk of developing metastatic disease. This article discusses its properties, efficacy and side-effects.

Read the full article.

Add yours ↓
Web design and marketing agency Leamington Spa